Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 3301 to 3303 of 3303 entries
Sorted by: Best Match Show Resources per page
Dibenzocyclooctadiene lignans from Kadsura coccinea alleviate APAP-induced hepatotoxicity via oxidative stress inhibition and activating the Nrf2 pathway in vitro.

Bioorganic chemistry

Yang Y, Jian Y, Cheng S, Jia Y, Liu Y, Yu H, Cao L, Li B, Peng C, Iqbal Choudhary M, Rahman AU, Wang W.
PMID: 34426147
Bioorg Chem. 2021 Oct;115:105277. doi: 10.1016/j.bioorg.2021.105277. Epub 2021 Aug 19.

Phytochemical investigation on the roots of Kadsura coccinea led to the isolation five previously unknown dibenzocyclooctadiene lignans, named heilaohusuins A-E (1-5). Their structures determined by NMR spectroscopy, HR-ESI-MS, and ECD spectra. Hepatoprotection effects of a series of dibenzocyclooctadiene derivatives...

Cite
Yang Y, Jian Y, Cheng S, et al. Dibenzocyclooctadiene lignans from Kadsura coccinea alleviate APAP-induced hepatotoxicity via oxidative stress inhibition and activating the Nrf2 pathway in vitro. Bioorg Chem. 2021;115:105277doi: 10.1016/j.bioorg.2021.105277.
Yang, Y., Jian, Y., Cheng, S., Jia, Y., Liu, Y., Yu, H., Cao, L., Li, B., Peng, C., Iqbal Choudhary, M., Rahman, A. U., & Wang, W. (2021). Dibenzocyclooctadiene lignans from Kadsura coccinea alleviate APAP-induced hepatotoxicity via oxidative stress inhibition and activating the Nrf2 pathway in vitro. Bioorganic chemistry, 115105277. https://doi.org/10.1016/j.bioorg.2021.105277
Yang, Yupei, et al. "Dibenzocyclooctadiene lignans from Kadsura coccinea alleviate APAP-induced hepatotoxicity via oxidative stress inhibition and activating the Nrf2 pathway in vitro." Bioorganic chemistry vol. 115 (2021): 105277. doi: https://doi.org/10.1016/j.bioorg.2021.105277
Yang Y, Jian Y, Cheng S, Jia Y, Liu Y, Yu H, Cao L, Li B, Peng C, Iqbal Choudhary M, Rahman AU, Wang W. Dibenzocyclooctadiene lignans from Kadsura coccinea alleviate APAP-induced hepatotoxicity via oxidative stress inhibition and activating the Nrf2 pathway in vitro. Bioorg Chem. 2021 Oct;115:105277. doi: 10.1016/j.bioorg.2021.105277. Epub 2021 Aug 19. PMID: 34426147.
Copy Download .nbib Format: NLM
Facile synthesis of recyclable 3D gelatin aerogel decorated with MIL-88B(Fe) for activation peroxydisulfate degradation of norfloxacin.

Journal of hazardous materials

Jing Y, Jia M, Xu Z, Xiong W, Yang Z, Peng H, Cao J, Xiang Y, Zhang C.
PMID: 34736183
J Hazard Mater. 2022 Feb 15;424:127503. doi: 10.1016/j.jhazmat.2021.127503. Epub 2021 Oct 14.

The application of traditional powder catalysts is limited by particle agglomeration and difficult recovery. In this work, a three-dimensional porous aerogel catalyst for organic pollutants degradation in water by activating peroxydisulfate (PDS) was successfully synthesized, which was obtained via...

Cite
Jing Y, Jia M, Xu Z, et al. Facile synthesis of recyclable 3D gelatin aerogel decorated with MIL-88B(Fe) for activation peroxydisulfate degradation of norfloxacin. J Hazard Mater. 2021;424:127503doi: 10.1016/j.jhazmat.2021.127503.
Jing, Y., Jia, M., Xu, Z., Xiong, W., Yang, Z., Peng, H., Cao, J., Xiang, Y., & Zhang, C. (2022). Facile synthesis of recyclable 3D gelatin aerogel decorated with MIL-88B(Fe) for activation peroxydisulfate degradation of norfloxacin. Journal of hazardous materials, 424127503. https://doi.org/10.1016/j.jhazmat.2021.127503
Jing, Ying, et al. "Facile synthesis of recyclable 3D gelatin aerogel decorated with MIL-88B(Fe) for activation peroxydisulfate degradation of norfloxacin." Journal of hazardous materials vol. 424 (2022): 127503. doi: https://doi.org/10.1016/j.jhazmat.2021.127503
Jing Y, Jia M, Xu Z, Xiong W, Yang Z, Peng H, Cao J, Xiang Y, Zhang C. Facile synthesis of recyclable 3D gelatin aerogel decorated with MIL-88B(Fe) for activation peroxydisulfate degradation of norfloxacin. J Hazard Mater. 2022 Feb 15;424:127503. doi: 10.1016/j.jhazmat.2021.127503. Epub 2021 Oct 14. PMID: 34736183.
Copy Download .nbib Format: NLM
Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC.

Frontiers in oncology

Liu S, Wu F, Li X, Zhao C, Jia Y, Jia K, Han R, Qiao M, Li W, Yu J, Zhou F, Xiong A, Chen B, Fan J, Ren S, Zhou C.
PMID: 33777802
Front Oncol. 2021 Mar 11;11:639947. doi: 10.3389/fonc.2021.639947. eCollection 2021.

BACKGROUND: Despite disappointing outcomes from immuno-monotherapy, studies reported that NSCLC patients with EGFR mutation may possibly benefit from combined immunotherapy. Whether the response to prior EGFR-TKI has association with the outcomes of subsequent immunotherapy remains unclear.PATIENTS AND METHODS: Advanced...

Cite
Liu S, Wu F, Li X, et al. Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. Front Oncol. 2021;11:639947doi: 10.3389/fonc.2021.639947.
Liu, S., Wu, F., Li, X., Zhao, C., Jia, Y., Jia, K., Han, R., Qiao, M., Li, W., Yu, J., Zhou, F., Xiong, A., Chen, B., Fan, J., Ren, S., & Zhou, C. (2021). Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. Frontiers in oncology, 11639947. https://doi.org/10.3389/fonc.2021.639947
Liu, Sangtian, et al. "Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC." Frontiers in oncology vol. 11 (2021): 639947. doi: https://doi.org/10.3389/fonc.2021.639947
Liu S, Wu F, Li X, Zhao C, Jia Y, Jia K, Han R, Qiao M, Li W, Yu J, Zhou F, Xiong A, Chen B, Fan J, Ren S, Zhou C. Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. Front Oncol. 2021 Mar 11;11:639947. doi: 10.3389/fonc.2021.639947. eCollection 2021. PMID: 33777802; PMCID: PMC7991800.
Copy Download .nbib Format: NLM
Showing 3301 to 3303 of 3303 entries